Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Joyce Wei
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Information Published In Science Translational Medicine Volume 14 | Issue 670 November 2022 Copyright Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an article distributed under the terms of the Science Journals Default License. Submission history Received: 25 May 2022 Accepted: 20 October 2022 Permissions Request permissions for this article.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
LATEST NEWS Dynamic bispecific duo Bispecific antibodies are being used for cancer immunotherapy because they target two different antigens thus facilitating T cell targeting to tumors. Odronextamab is a CD20xCD3 bispecific antibody that shows promising activity in patients with diffuse large B cell lymphoma (DLBCL), but not all patients achieve complete responses, and there remains a high unmet need in the setting of relapsed/refractory disease. Wei et al. (p.
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
LATEST NEWS Tuning up CAR T cells Despite their success at treating hematological malignancies, CAR T cells have not been as effective in treating solid tumors. This is, in part, due to loss of stemness and development of an exhausted phenotype after infusion. Here, Jung et al. investigated a strategy to reverse this phenotype based on analysis of CAR T cells used in a clinical trial for metastatic prostate cancer.
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
LATEST NEWS Test driving CAR T cells CAR T cells have already been through multiple generations, with each iteration improving signaling through the receptor. However, a strategy to broadly test multiple candidate intracellular signaling domains would allow for even better optimization. Here, Goodman et al. have developed CAR Pooling, a multiplexed approach to rapidly identify the top CAR signaling domains.
Interleukin-2-based therapies in cancer
LATEST NEWS Abstract Molecular insights into the mechanism of beneficial and adverse effects of interleukin-2 (IL-2) have resulted in the development of improved IL-2 formulations with IL-2 receptor bias and tissue-targeting properties. Several of these compounds are currently in clinical development and are ushering IL-2 therapy into the current era of cancer immunotherapy. Get full access to this article View all available purchase options and get full access to this article.
Advancing beyond the twists and turns of T cell exhaustion in cancer
LATEST NEWS Abstract Chronic antigen stimulation leads to T cell exhaustion. Nutrient restrictions and other suppressive factors in the tumor microenvironment further exacerbate T cell dysfunction. Better understanding of heterogeneity and dynamics of exhausted CD8 T cells will guide novel therapies that modulate T cell differentiation to achieve more effective antitumor responses. Get full access to this article View all available purchase options and get full access to this article.
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
LATEST NEWS Abstract Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice. Get full access to this article View all available purchase options and get full access to this article.
What’s next for cancer vaccines
LATEST NEWS Abstract Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments. Get full access to this article View all available purchase options and get full access to this article.
In vivo gene immunotherapy for cancer
Information Published In Science Translational Medicine Volume 14 | Issue 670 November 2022 Copyright Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an article distributed under the terms of the Science Journals Default License. Submission history Received: 15 April 2022 Accepted: 20 October 2022 Permissions Request permissions for this article. Acknowledgments We thank A.
Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis
Information Published In Science Translational Medicine Volume 14 | Issue 669 November 2022 Copyright Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an article distributed under the terms of the Science Journals Default License. Submission history Received: 24 March 2022 Accepted: 11 October 2022 Permissions Request permissions for this article. Acknowledgments We thank E.
Translational gaps and opportunities for medical wearables in digital health
LATEST NEWS Abstract A confluence of advances in biosensor technologies, enhancements in health care delivery mechanisms, and improvements in machine learning, together with an increased awareness of remote patient monitoring, has accelerated the impact of digital health across nearly every medical discipline.
mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
Information Published In Science Translational Medicine Volume 13 | Issue 620 November 2021 Copyright Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an article distributed under the terms of the Science Journals Default License. Submission history Received: 15 June 2021 Accepted: 22 September 2021 Permissions Request permissions for this article.
Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses
Order of immunotherapy matters Immune checkpoint blockade is clinically successful in various cancer types, yet many treated patients recur; thus, determining effective combination therapies that induce systemic antitumor immunity is crucial. Immune checkpoint blockade combined with local radiation can improve antitumor responses, but it remains unclear how the sequence of these therapies alters efficacy. Here, Wei et al.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Joyce
Contact Joyce, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack